Dilanubicel
Acute Myeloid Leukemia, Del(5q31-Q32)
Explore 5 assets in Acute Myeloid Leukemia, Del(5q31-Q32) →Floatz Rating
CCC52/100
Confidence
Indicative
Sponsor
Nohla Therapeutics, Inc.
Modality
Cell therapy
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
37High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01175785CT.gov Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies | — | Completed | — | — | — |
NCT01031368CT.gov Clofarabine, Cytarabine, and Filgrastim Followed by Infusion of Non-HLA Matched Ex Vivo Expanded Cord Blood Progenitors in Treating Patients With Acute Myeloid Leukemia | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Acute Myeloid Leukemia, Del(5q31-Q32)
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Dilanubicel (this asset) | Nohla Therapeutics, Inc. | P2 | CCC · 52 |
| Etoposide | Alice Mims | P3 | BBB |
| Idarubicin | Bruno C. Medeiros | P2 | BBB |
| Cytarabine | Alice Mims | P3 | BBB |
| Cyclophosphamide | Sumithira Vasu | P3 | BBB |
| Fludarabine | Rutgers, The State University of New Jersey | P3 | BBB |
| Cyclosporin A | National Cancer Institute (NCI) | P3 | BBB |
| Daunomycin | National Cancer Institute (NCI) | P3 | BBB |
| Busulfanum | University of Wisconsin, Madison | P3 | BB |
+42 more in the Acute Myeloid Leukemia, Del(5q31-Q32) cohort
Other indications for Dilanubicel
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Acute Myeloid Leukemia With Abnormal Bone Marrow Eosinophils Inv(16)(P13q22) Or T(16;16)(P13;Q22) | — | P2 | CCC · 52 |
| Acute Promyelocytic Leukemia | — | P2 | CCC · 52 |
| Acute Myeloid Leukemia With 11q23 Abnormalities | — | P2 | CCC · 52 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Dilanubicel in Acute Myeloid Leukemia, Del(5q31-Q32). Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/dilanubicel-acute-myeloid-leukemia-del5q31-q32
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →